Patients HCP
This site is for US Health Care Professionals only.
Coverage just got better! The 3 largest PBMs now cover Scemblix in the 1st line1. For adults with newly diagnosed Ph+ CML-CP. Tough on CML. With a different touch. As the first and only inhibitor that binds to the ABL myristoyl pocket, Scemblix offers a different approach. PBM, pharmacy benefit manager; Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase; TKI, tyrosine kinase inhibitor. #1 most prescribed TKI for Ph+ CML-CP. Not an actual patient.
NCCN Category 1, * preferred4.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend asciminib (SCEMBLIX®) as a Category 1, Preferred first-line treatment option for newly diagnosed adult patients with Ph+ CML-CP across risk groups (low-, intermediate-, or high-risk score).†,‡
 

*Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analysis), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
†NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
‡See the NCCN Guidelines® for detailed recommendations, including other preferred treatment options.

Imagine what is possible with SCEMBLIX

SCEMBLIX was studied vs all standard-of-care TKIs§ in patients with newly diagnosed Ph+ CML-CP in ASC4FIRST2,5,||

§Imatinib, nilotinib, dasatinib, and bosutinib.
 

SCEMBLIX delivered superior response rates at Weeks 48 and 962

MMR rates at Week 48. (two primary end points) 68% Scemblix (95% CI, 67-74) (n=201) vs 49% IS-TKIs± (all) (95% CI, 42-56) (n=204). 69% Scemblix (95% CI, 59-78) (n=101) vs 40% IS-TKIs± (imatinib) (95% CI, 31-50) (n=102).
MMR rate at Week 96. 74% Scemblix (95% CI, 68-80) (n=201) vs 52% IS-TKIs (all) (95% CI, 45-59) (n=204). 76% Scemblix (95% CI, 67-84) (n=101) vs 47% IS-TKIs (imatinib) (95% CI, 37-57) (n=102).

IS-TKIs included imatinib (400 mg once daily) and other TKIs of nilotinib (300 mg twice daily), dasatinib (100 mg once daily), or bosutinib (400 mg once daily).2
#Estimated using a common risk difference stratified by PRS-TKI and baseline ELTS risk groups.2
**Adjusted P-value using a Cochran-Mantel-Haenszel 1-sided test stratified by PRS-TKI and baseline ELTS risk groups.2
††Adjusted P-value using a Cochran-Mantel-Haenszel 1-sided test stratified by baseline ELTS risk groups.2

See the efficacy data

At Week 96, the discontinuation rate due to ARs was >2X lower with SCEMBLIX vs standard-of-care TKIs (all)2,6

Permanent discontinuation due to ARs (all-grade) at Week 96. 5% Scemblix (n=200) vs 12.9% IS-TKIs (all) (n=201). Dosage interruptions of Scemblix due to an AR occurred in 33% of patients. Dose reductions of Scemblix due to an AR occurred in 6% of patients. The most common ARs (≥20%) in patients who received Scemblix were musculoskeletal pain and rash. Serious adverse reactions occurred in 14.5% of patients who received Scemblix.

AR, adverse reaction; CML, chronic myeloid leukemia; ELTS, EUTOS long-term survival; EUTOS, EUropean Treatment Outcome Study; IS-TKI, Investigator-selected tyrosine kinase inhibitor; MMR, major molecular response; NCCN, National Comprehensive Cancer Network; qd, once daily.

Explore the safety profile

||ASC4FIRST is a multicenter, randomized, active-controlled, open-label study of 405 adults with newly diagnosed Ph+ CML-CP. Investigators, in consultation with patients, preselected the appropriate TKI and evaluated ELTS risk scores. Patients were then stratified by preselected TKI and ELTS score, then randomized (1:1) to receive either SCEMBLIX or an Investigator-selected TKI (imatinib, nilotinib, bosutinib, or dasatinib). 201 patients received SCEMBLIX at 80 mg qd, and 204 patients received IS-TKIs until unacceptable toxicity or treatment failure occurred.2,5

References: 1. Data on file. MMIT coverage lives data. Novartis Pharmaceuticals Corp; 2025. 2. Scemblix. Prescribing information. Novartis Pharmaceuticals Corp. 3. Data on file. IQVIA CML Market Sizing NBRx. Novartis Pharmaceuticals Corp; 2025. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.1.2026. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 16, 2025. To view the most recent and complete version of the guidelines, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 5. Data on file. CABL001J12301 clinical study report (Week 48 analysis). Novartis Pharmaceuticals Corp; 2022. 6. Data on file. ABL001J1 SCS Appendix 2. Novartis Pharmaceuticals Corp; 2025.